Tandukar Srijan, Kim Catherine, Kalra Kartik, Verma Siddharth, Palevsky Paul M, Puttarajappa Chethan
Willis-Knighton Medical Center, Shreveport, LA.
Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA.
Kidney Med. 2020 Jun 15;2(4):437-449. doi: 10.1016/j.xkme.2020.05.007. eCollection 2020 Jul-Aug.
RATIONALE & OBJECTIVE: In patients with severe hyponatremia in the setting of acute kidney injury or end-stage kidney disease, continuous renal replacement therapy (CRRT) using standard-sodium (140 mEq/L) fluids may lead to excessively rapid correction of plasma sodium concentration. Use of dialysate and replacement fluids with reduced sodium concentrations can provide a controlled rate of correction of plasma sodium concentration.
We performed a single-center retrospective analysis of the safety and effectiveness of this approach in patients with plasma sodium concentrations ≤ 126 mEq/L who underwent CRRT for 24 or more hours using low-sodium (119 or 126 mEq/L) dialysate and replacement fluids. Change in plasma sodium level was assessed at 24 and 48 hours after initiation of low-sodium CRRT and at the end of treatment.
SETTING & PARTICIPANTS: Between January 2016 and June 2018, a total of 23 hyponatremic patients underwent continuous venovenous hemodiafiltration using low-sodium dialysate and replacement fluids; 4 patients were excluded from analysis because of CRRT duration less than <24 hours.
The 19 patients included in the study had a mean age of 56 years, 11 (58%) were men, and 15 (79%) were white. The initial mean plasma sodium level was 121 mEq/L and the initial CRRT effluent dose was 27 mL/kg/h. Only 2 (11%) patients had an increase in plasma sodium concentration > 6 mEq/L at 24 hours. Mean changes in plasma sodium levels at 24 and 48 hours and at the time of CRRT discontinuation were 3, 3, and 6 mEq/L, respectively. None of the patients developed osmotic demyelination syndrome.
Key limitations were small sample size and lack of a control group.
Use of low-sodium dialysate and replacement fluids is a safe strategy for the prevention of overly rapid correction of plasma sodium levels in hyponatremic patients undergoing CRRT.
在急性肾损伤或终末期肾病背景下的严重低钠血症患者中,使用标准钠(140 mEq/L)液体进行连续性肾脏替代治疗(CRRT)可能导致血浆钠浓度纠正过快。使用钠浓度降低的透析液和置换液可控制血浆钠浓度的纠正速率。
我们对血浆钠浓度≤126 mEq/L且使用低钠(119或126 mEq/L)透析液和置换液进行CRRT达24小时或更长时间的患者,进行了该方法安全性和有效性的单中心回顾性分析。在低钠CRRT开始后24小时和48小时以及治疗结束时评估血浆钠水平的变化。
2016年1月至2018年6月期间,共有23例低钠血症患者使用低钠透析液和置换液进行连续性静脉-静脉血液透析滤过;4例患者因CRRT持续时间不足24小时被排除在分析之外。
纳入研究的19例患者平均年龄为56岁,11例(58%)为男性,15例(79%)为白人。初始平均血浆钠水平为121 mEq/L,初始CRRT超滤剂量为27 mL/kg/h。仅2例(11%)患者在24小时时血浆钠浓度升高>6 mEq/L。CRRT开始后24小时、48小时及CRRT停止时血浆钠水平的平均变化分别为3、3和6 mEq/L。所有患者均未发生渗透性脱髓鞘综合征。
主要局限性为样本量小且缺乏对照组。
对于接受CRRT的低钠血症患者,使用低钠透析液和置换液是预防血浆钠水平过快纠正的安全策略。